• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Diabetes/Metabolism Research And Reviews

    Diabetes/Metabolism Research And Reviews

    JournalISSN 1520-7552eISSN 1099-0895中科院 医学 3区

    年发文量

    研究主题

    论文(4156)

    排序
    1Interobserver Reliability of the Rotterdam Diabetic Foot Study Test Battery for Assessing Cutaneous Sensibility
    Nadine Boers, Isabelle M. L. P. Kamm, Manuel Castro Cabezas, T. M. Fakkel,Willem D. Rinkel,J. Henk Coert

    ABSTRACT Aim The Rotterdam Diabetic Foot (RDF) Test Battery was developed to assess sensory function and predict the risk of diabetic foot ulceration and falls. We evaluated its interobserver reliability in patients with diabetic sensorimotor polyneuropathy. Methods The RDF Test Batteries include a continuous and dichotomous 39‐item scale and a shorter dichotomous 13‐item scale. The 39‐item test battery was administered by two investigators, and the 13‐item test battery by five investigators with varying experience. Percentage agreement, Cohen's kappa coefficient ( κ ) and intraclass correlation coefficient (ICC) were calculated, including agreement in ulcer risk classification based on predefined cut‐off values derived from the 39‐item and 13‐item test battery sum scores; incident ulcer outcomes were not collected. Results The continuous 39‐item test battery ( n = 36 test batteries) showed low to high exact agreement (33.9%–100%), poor item‐level ICCs (0.04–0.19), and small median between‐observer differences. Dichotomous 39‐item ( n = 56) and 13‐item test batteries ( n = 310) showed low percentage agreement (42.9% and 47.1%) but good reliability (ICC 0.83, 95% CI: 0.67–0.92 and 0.80, 95% CI: 0.73–0.85). Cut‐off based classification of ulcer risk of the 39‐item and 13‐item test batteries showed acceptable to high agreement (96.4% and 87.1%) and substantial reliability ( κ = 0.67 and 0.73, both p < 0.001). Conclusion Both instruments showed good reproducibility in sensory staging, although this varied using scoring approach and analysis level. The dichotomous test batteries showed good reliability at the sum‐score level, whereas exact agreement for the continuous 39‐item test battery and reliability of several individual items were limited. Clinical use and ulcer risk classification require further evaluation before routine implementation.

    2026
    引用
    AI阅读
    加入学术空间
    2Effectiveness and Safety of Once‐Weekly Semaglutide 2.4 Mg in Korean Adults with Obesity or Overweight: A Multicenter Retrospective Real‐World Study (RE‐SEMA‐K Study)
    Yu‐Jin Kwon,Young‐Sang Kim,Hae‐Jin Ko, Susie Jung,Yoon Jeong Cho,Ji‐Eun Song,Sung‐Bum Lee,Ga Eun Nam,Jungha Park,Myung Jae Seo,Jong Koo Kim,Seo Young Kang,

    ABSTRACT Aims To evaluate the effectiveness and treatment patterns of once‐weekly semaglutide 2.4 mg in South Korean adults with overweight or obesity in real‐world practice. Materials and Methods This multicenter retrospective study analysed electronic medical records from 17 centres in South Korea. Included were adults (≥ 19 years) with BMI ≥ 25 kg/m 2 , or ≥ 23 kg/m 2 with obesity‐related comorbidities. Primary endpoints were changes in body weight at 3, 6, 9, and 12 months. Secondary outcomes included body composition, categorical weight loss, cardiometabolic changes, treatment persistence, safety, and changes in liver function. Results Among 1160 patients (40.9% with prior obesity medications), semaglutide treatment induced progressive weight reduction (−5.85%, −9.55%, −11.43%, and −13.16% at 3, 6, 9, and 12 months). Greater reduction occurred in women, younger patients, and those without T2D or prior obesity medication. By 6 months, cardiometabolic, liver function, and body composition parameters improved, with preferential loss of fat over lean mass (all p < 0.001). Starting doses varied across patients (0.25 mg, 55.9%; 0.5 mg, 30.4%; 1.0 mg, 11.9%), with rapid dose escalation reaching the maintenance dose (2.4 mg) in a mean of 3.52 months, reflecting individualised real‐world dosing. Mean treatment duration was 4.9 months. Adverse events, predominantly transient gastrointestinal symptoms, occurred in approximately 22% of patients. Conclusions Semaglutide 2.4 mg achieved substantial weight loss in South Korean adults with overweight or obesity. Weight reduction was comparable to the STEP 6 trial despite shorter follow‐up (4.9 months), substantial prior obesity medication exposure, and accelerated dose escalation, supporting robust real‐world effectiveness.

    2026
    引用
    AI阅读
    加入学术空间
    3Adults with Type 1 Diabetes Are Less Physically Active Than Adults Without Diabetes: A Systematic Review and Meta‐Analysis
    Antonio García‐Hermoso,Jacinto Muñoz‐Pardeza,Ignacio Hormazábal‐Aguayo,Yasmin Ezzatvar

    ABSTRACT Aims Physical activity is central to the management of type 1 diabetes, yet diabetes‐specific barriers may reduce habitual activity. We systematically reviewed and meta‐analysed studies comparing physical activity and sedentary behaviour in adults with type 1 diabetes and adults without diabetes. Material and Methods MEDLINE, Embase, and SPORTDiscus were searched from inception to 24 July 2026. Random‐effects models were used to pool standardised mean differences for continuous outcomes and odds ratios (OR) for meeting physical activity recommendations or study‐defined active criteria. Results Sixteen publications representing 14 independent cohorts and 3335 participants were included (54.2% females). Adults with type 1 diabetes had lower total physical activity than adults without diabetes (12 studies; Hedges g = −0.13; 95% confidence interval, −0.22 to −0.05; p = 0.001), with no detected heterogeneity. They also had lower estimated odds of meeting a physical activity criterion, although the association was not statistically significant (4 studies; OR = 0.77; 95% confidence interval, 0.58–1.02; p = 0.066). Mean age, diabetes duration and glycated haemoglobin were not associated with between‐group differences in total physical activity. Data were insufficient to pool sedentary behaviour, steps or intensity‐specific outcomes. Conclusions Adults with type 1 diabetes engage in slightly less total physical activity than adults without diabetes, although evidence regarding adherence to physical activity recommendations remains inconclusive. The absence of population‐based studies limits the generalisability of these findings and highlights the need for representative studies using standardised device‐based assessments.

    2026
    引用
    AI阅读
    加入学术空间
    4Biomechanical Evolution in the Neuropathic Diabetic Foot: A Scoping Review of Gait and Kinetic‐Kinematic‐Structural Adaptations in Diabetes
    G. Di Stasio, R. Colella, D. G. Armstrong, A. Bellingeri, A. De Mola, G. Montini, V. Scotti, A. De Silvestri, F. Campitiello

    ABSTRACT Background Gait alterations and biomechanical changes associated with diabetic peripheral polyneuropathy have been described in the literature, but the available evidence remains fragmented. It does not provide a comprehensive overview of how the reported biomechanical patterns differ across clinical stages of the Neuropathic Diabetic Foot (NDF). Mapping these patterns may support an improved understanding of the biomechanical mechanisms underlying increased ulceration risk. Aim This scoping review aims to explore and synthesise the existing literature on changes in gait and foot biomechanics in people with diabetes in association with Diabetic Peripheral Neuropathy (DPN) and across its reported clinical stages. Methods The scoping review was conducted in accordance with the JBI methodology for scoping reviews and in line with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses extension for Scoping Reviews (PRISMA‐ScR). The population included adults with diabetes and peripheral neuropathy, without active foot ulceration, who were managed in community or outpatient settings. The concept of interest is gait and foot‐biomechanical alterations associated with diabetic neuropathy in clinical and biomechanical assessment contexts. A comprehensive search was conducted in PubMed, EMBASE, CINAHL, PEDro, and the Cochrane Library, complemented by grey literature sources including the Trip Medical Database, NICE, and the Guidelines International Network (GIN). Studies published within the last 11 years were considered (2014/12–2026/04). Data were charted and synthesised using a descriptive and narrative approach. Results From 2044 initial records, 44 sources met the eligibility criteria. An updated search conducted in April 2026 identified 6 additional eligible sources, resulting in 50 included sources. The evidence mapped across three principal themes: gait and lower‐limb kinematic alterations, changes in plantar loading and joint kinetics, and structural or functional changes of the foot. No included study directly evaluated whether the identified biomechanical alterations predicted the subsequent development of Charcot neuro‐osteoarthropathy. Conclusions To our knowledge, this is the first scoping review to map structural, kinematic, kinetic, and plantar‐loading findings within an integrated biomechanical framework of the neuropathic diabetic foot. Because the evidence was predominantly cross‐sectional, the proposed relationships should be interpreted as a conceptual synthesis rather than a demonstrated longitudinal progression. These findings highlight the need for longitudinal studies to investigate the temporal evolution of biomechanical alterations in the neuropathic diabetic foot.

    2026
    引用
    AI阅读
    加入学术空间
    5A Novel Paradigm for Adult‐Onset Type 1 Diabetes: Once‐Weekly Basal Insulin and SGLT‐2 Inhibition to Harness Residual Β‐cell Function
    Paolo Pozzilli,Richard David Leslie

    ABSTRACT Type 1 diabetes (T1D) in adults is characterised by a less aggressive disease course than in children. Most patients retain preserved C‐peptide (> 02 nmol/L) and some of them benefit from a protracted phase without the need for insulin. Here, we propose a hypothesis‐generating therapeutic paradigm with once‐weekly basal insulin combined with an SGLT2 inhibitor (SGLT2is) as initial therapy in T1D patients with preserved C‐peptide. Once‐weekly basal insulin, approved in Europe and now also in the US, confirm comparable HbA1c reductions to insulin degludec or glargine, albeit always alongside prandial insulin. SGLT2is, approved as adjuncts in T1D in select regions, can control prandial peaks without boluses. No trials have tested the combination of weekly insulin with SGLT2is in adult T1D patients. Nonetheless, the rationale is robust especially in adults with C‐peptide > 0·2 nmol/L. In this respect, we urge proof‐of‐concept trials of 12‐months randomised studies in adults ≥ 18 years, to evaluate this combination.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4156 篇论文

    高被引作者

    作者引用发文
    Jan Apelqvist590129
    Nicolaas C. Schaper497431
    Sicco A. Bus458432
    Benjamin Lipsky401517
    Robert Hinchliffe377022
    Paolo Pozzilli317786
    Lawrence A. Lavery314915
    Matilde Monteiro-Soares305320
    Jaap J. Van Netten305122
    Eric Senneville301620

    高产作者

    作者引用发文
    Paolo Pozzilli317786
    Zhiguang Zhou236264
    Jianping Weng126241
    Dalong Zhu132235
    Xia Li77732
    Raffaella Buzzetti125432
    Sicco A. Bus458432
    Nicolaas C. Schaper497431
    Jinhua Yan23430
    Weiping Jia149030

    相关期刊

    Journal of Diabetes and its Complications
    Diabetes Research and Clinical Practice
    Diabetes, Obesity and Metabolism
    Diabetology & metabolic syndrome
    Journal of diabetes
    World journal of diabetes
    Journal of diabetes investigation
    Journal of diabetes research
    BMJ open diabetes research & care
    Current Diabetes Reviews